Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
Purpose of review: Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dr
Myelodysplastic Syndromes (MDS)
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
Introduction: Azacitidine Azacitidine: It works by reducing the amount of methylation in the body.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
Mutations in UBA1, which are disease-defining for VEXAS syndrome, have been reported in patients diagnosed with myelodysplastic syndromes myelody
T-cell dysfunctions in myelodysplastic syndromes
Escape from immune surveillance is a hallmark of cancer. Immune deregulation caused by intrinsic and extrinsic cellular factors, such as altered T-cell functions, leads to immune exhaustion, loss of immune surveillance, and clonal proliferation of tumoral cells. The T-cell immune system contributes to the pathogenesis, maintenance, and progression of myelodysplastic syndrome (MDS).
Kristen Schratz, MD
Institution
Johns Hopkins University
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Pediatric
Yasmin Abaza, MD
Institution
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Stephen Chung, MD
Institution
UT Southwestern Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Stephen Chung, M.D., is an Assistant Professor in the Department of Internal Medicine and the Children’s Research Institute at UT Southwestern Medical Center. He specializes in the care of patients with the myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr. Chung earned his medical degree at Washington University School of Medicine in St. Louis. He completed a residency in internal medicine at Massachusetts General Hospital followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), where he remained as a faculty member of the Leukemia
Neal Young, MD
Institution
National Heart, Lung, and Blood Institute - National Institutes of Health
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Neal Young received a A.B. cum laude from Harvard College in 1967 and his M.D. in 1971 from the Johns Hopkins School of Medicine. He did post-graduate medical training at Massachusetts General Hospital and Barnes Hospital at Washington University in St. Louis before joining the NHLBI in 1981. He is a Master of the American College of Physicians and has accrued many academic honors. His efforts as a US Government employee were recognized with Samuel J. Heyman Service to America Medal in Science and the Environment. Dr. Young has authored over 280 original scientific and medical articles in peer
David B. Sykes, MD, PhD
Institution
Mass General Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
David completed his undergraduate training in Biochemistry at the University of Alberta in Edmonton, Canada. He entered the Medical Scientist Training Program (M.D., Ph.D.) at the University of California San Diego and carried out his Ph.D. research with Dr. Mark Kamps where he became interested in the problems that arise during white blood cell development. David did his internship and residency at the Massachusetts General Hospital as well as a year as a Chief Medical Resident in the Department of Internal Medicine. He was a Hematology and Oncology fellow in the combined Dana-Farber Cancer
Zhuoer Xie, MD, MS
Institution
Moffitt Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Xie is a hematologist and assistant member in the Moffitt Cancer Center Malignant Hematology Department. Dr. Xie completed her hematology/oncology fellowship training at the Mayo Clinic, Rochester, MN, Master of Science in Clinical Research and Geriatric fellowship training at the UCLA, Ronald Reagan Medical Center. She focuses on treating myeloid malignancies and precursor stages, including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia (CCUS), MDS, MPN, CMML, and Acute Leukemia. Her research focuses on clinical and translational science, including identifying